Valerio Therapeutics Société anonyme (EPA: ALVIO)

ALVIO Statistics

Total Valuation

Valerio Therapeutics Société anonyme has a market cap or net worth of EUR 11.21 million. The enterprise value is 20.43 million.

Market Cap	11.21M
Enterprise Value	20.43M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

Valerio Therapeutics Société anonyme has 153.97 million shares outstanding. The number of shares has increased by 40.39% in one year.

Current Share Class	n/a
Shares Outstanding	153.97M
Shares Change (YoY)	+40.39%
Shares Change (QoQ)	+6.29%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.28%
Float	62.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.13
PB Ratio	2.79
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.04
EV / Sales	10.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.24

Financial Position

The company has a current ratio of 0.90, with a Debt / Equity ratio of 3.29.

Current Ratio	0.90
Quick Ratio	0.79
Debt / Equity	3.29
Debt / EBITDA	n/a
Debt / FCF	-0.80
Interest Coverage	-187.14

Financial Efficiency

Return on equity (ROE) is -144.55% and return on invested capital (ROIC) is -41.58%.

Return on Equity (ROE)	-144.55%
Return on Assets (ROA)	-30.61%
Return on Capital (ROIC)	-41.58%
Revenue Per Employee	49,711
Profits Per Employee	-517,316
Employee Count	19
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.00% in the last 52 weeks. The beta is 1.66, so Valerio Therapeutics Société anonyme's price volatility has been higher than the market average.

Beta (5Y)	1.66
52-Week Price Change	-60.00%
50-Day Moving Average	0.08
200-Day Moving Average	0.10
Relative Strength Index (RSI)	29.17
Average Volume (20 Days)	38,311

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Valerio Therapeutics Société anonyme had revenue of EUR 1.89 million and -19.66 million in losses. Loss per share was -0.12.

Revenue	1.89M
Gross Profit	1.41M
Operating Income	-17.97M
Pretax Income	-19.64M
Net Income	-19.66M
EBITDA	-16.46M
EBIT	-17.97M
Loss Per Share	-0.12

Balance Sheet

The company has 4.00 million in cash and 13.22 million in debt, giving a net cash position of -9.22 million or -0.06 per share.

Cash & Cash Equivalents	4.00M
Total Debt	13.22M
Net Cash	-9.22M
Net Cash Per Share	-0.06
Equity (Book Value)	4.02M
Book Value Per Share	0.03
Working Capital	-969,000

Cash Flow

In the last 12 months, operating cash flow was -16.31 million and capital expenditures -126,000, giving a free cash flow of -16.44 million.

Operating Cash Flow	-16.31M
Capital Expenditures	-126,000
Free Cash Flow	-16.44M
FCF Per Share	-0.11

Margins

Gross Margin	74.75%
Operating Margin	-951.03%
Pretax Margin	-1,039.76%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-870.09%

Dividends & Yields

Valerio Therapeutics Société anonyme does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.39%
Shareholder Yield	-40.39%
Earnings Yield	-169.74%
FCF Yield	-146.63%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Valerio Therapeutics Société anonyme has an Altman Z-Score of -3.63. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.63
Piotroski F-Score	n/a